ANI Pharma acquires Vancocin assets from Shire

2 August 2014
mergers-acquisitions-big

US generic drugmaker ANI Pharmaceuticals (Nasdaq: ANIP) says it has acquired the US rights for the antibiotic Vancocin (vancomycin HCl) 125mg and 250mg capsules from Shire (LSE: SHP), the Ireland-based pharma company that has just succumbed to a  $53 billion takeover offer from AbbVie (NYSE: ABBV).

In addition, ANI acquired from Shire approved Abbreviated New Drug Applications for the currently non-marketed products vancomycin injectable 500mg, 1gm and 10gm ($45 million in 2013 market value, per IMS Health) and vancomycin oral solution 250mg and 500mg.

Pays $11 million for Vancocin rights

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics